A novel blood-pooling MR contrast agent: Carboxymethyl-diethylaminoethyl dextran magnetite

Sonoda,Akinaga; Nitta,Norihisa; Tsuchiya,Keiko; Nitta‑Seko,Ayumi; Ohta,Shinichi; Otani,Hideji; Murata,Kiyoshi

doi:10.3892/mmr.2016.5874

A novel blood-pooling MR contrast agent: Carboxymethyl-diethylaminoethyl dextran magnetite

Authors:
- Akinaga Sonoda
- Norihisa Nitta
- Keiko Tsuchiya
- Ayumi Nitta‑Seko
- Shinichi Ohta
- Hideji Otani
- Kiyoshi Murata
View Affiliations

Affiliations: Department of Radiology, Shiga University of Medical Science, Otsu, Shiga 520‑2192, Japan
Published online on: October 21, 2016 https://doi.org/10.3892/mmr.2016.5874
Pages: 5195-5198

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gadofosveset trisodium is available as a prolonged pooling vascular contrast agent for magnetic resonance imaging. As gadolinium (Gd)-based agents may increase the risk for nephrogenic systemic fibrosis in patients with severe renal insufficiency, the present study synthesized carboxymethyl-diethylaminoethyl dextran magnetite (CMEADM) particles as a blood-pooling, non-Gd‑based contrast agent. CMEADM particles carry a negative or positive charge due to the binding of amino and carboxyl groups to the hydroxyl group of dextran. The present study evaluated whether the degree of charge alters the blood‑pooling time. The evaluation was performed by injecting four groups of three Japanese white rabbits each with CMEADM‑, CMEADM2‑, CMEADM+ (surface charges: ‑10.4, ‑41.0 and +9.6 mV, respectively) or with ultrasmall superparamagnetic iron oxide (USPIO; ‑11.5 mV). The relative signal intensity (SIrel) of each was calculated using the following formula: SIrel = (SI post‑contrast ‑ SI pre‑contrast / SI pre‑contrast) x 100. Following injection with the CMEADMs, but not with USPIO, the in vivo pooling time was prolonged to >300 min. No significant differences were attributable to the electric charge among the CMEADM‑, CMEADM2‑ or and CMEADM+ particles when analyzed with analysis of variance and Tukey's HSD test. Taken together, all three differently‑charged CMEADM2 particles exhibited prolonged vascular enhancing effects, compared with the USPIO. The degree of charge of the contrast agents used in the present study did not result in alteration of the prolonged blood pooling time.

View Figures

View References

1	Allkemper T, Bremer C, Matuszewski L, Ebert W and Reimer P: Contrast-enhanced blood-pool MR angiography with optimized iron oxides: Effect of size and dose on vascular contrast enhancement in rabbits. Radiology. 223:432–438. 2002. View Article : Google Scholar : PubMed/NCBI
2	Bremerich J, Bilecen D and Reimer P: MR angiography with blood pool contrast agents. Eur Radiol. 17:3017–3024. 2007. View Article : Google Scholar : PubMed/NCBI
3	Leung K: Ultrasmall superparamagnetic iron oxide nanoparticles conjugated with Ile-Pro-Leu-Pro-Phe-Tyr-AsnMolecular imaging and contrast agent database (MICAD). Bethesda (MD): Fed. 23–2010
4	Bryson J, Reineke JW and Reineke TM: Macromolecular imaging agents containing lanthanides: Can conceptual promise lead to clinical potential? Macromolecules. 45:8939–8952. 2012. View Article : Google Scholar : PubMed/NCBI
5	Grist TM, Korosec FR, Peters DC, Witte S, Walovitch RC, Dolan RP, Bridson WE, Yucel EK and Mistretta CA: Steady-state and dynamic MR angiography with MS-325: Initial experience in humans. Radiology. 207:539–544. 1998. View Article : Google Scholar : PubMed/NCBI
6	Weller A, Barber JL and Olsen OE: Gadolinium and nephrogenic systemic fibrosis: An update. Pediatr Nephrol. 29:1927–1937. 2014. View Article : Google Scholar : PubMed/NCBI
7	Xiao W, Lin J, Li M, Ma Y, Chen Y, Zhang C, Li D and Gu H: Prolonged in vivo circulation time by zwitterionic modification of magnetite nanoparticles for blood pool contrast agents. Contrast Media Mol Imaging. 7:320–327. 2012. View Article : Google Scholar : PubMed/NCBI
8	Nitta N, Tsuchiya K, Sonoda A, Ota S, Ushio N, Takahashi M, Murata K and Nohara S: Negatively charged superparamagnetic iron oxide nanoparticles: A new blood-pooling magnetic resonance contrast agent. Jpn J Radiol. 30:832–839. 2012. View Article : Google Scholar : PubMed/NCBI
9	Tsuchiya K, Nitta N, Sonoda A, Nitta-Seko A, Ohta S, Takahashi M, Murata K, Mukaisho K, Shiomi M, Tabata Y and Nohara S: Evaluation of atherosclerotic lesions using dextran- and mannan-dextran-coated USPIO: MRI analysis and pathological findings. Int J Nanomedicine. 7:2271–2280. 2012. View Article : Google Scholar : PubMed/NCBI
10	Tsuchiya K, Nitta N, Sonoda A, Otani H, Takahashi M, Murata K, Shiomi M, Tabata Y and Nohara S: Atherosclerotic imaging using 4 types of superparamagnetic iron oxides: New possibilities for mannan-coated particles. Eur J Radiol. 82:1919–1925. 2013. View Article : Google Scholar : PubMed/NCBI
11	Arbab AS, Liu W and Frank JA: Cellular magnetic resonance imaging: Current status and future prospects. Expert Rev Med Devices. 3:427–439. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kawaguchi T, Hanaichi T, Hasegawa M and Maruno S: Dextran-magnetite complex: Conformation of dextran chains and stability of solution. J Mater Sci Mater Med. 12:121–127. 2001. View Article : Google Scholar : PubMed/NCBI
13	Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C and Corot C: Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: Mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol. 39:56–63. 2004. View Article : Google Scholar : PubMed/NCBI
14	Neuwelt EA, Hamilton BE, Varallyay CG, Rooney WR, Edelman RD, Jacobs PM and Watnick SG: Ultrasmall superparamagnetic iron oxides (USPIOs): A future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int. 75:465–474. 2009. View Article : Google Scholar : PubMed/NCBI
15	Corot C, Port M, Guibert I, Robert P, Raynal I, Robic C, Raynaud JS, Prigent P, Dencausse A, et al: Superparamagnetic contrast agents. 1st. London: CRC Press; pp. 59–84. 2007
16	Jo J, Aoki I and Tabata Y: Design of iron oxide nanoparticles with different sizes and surface charges for simple and efficient labeling of mesenchymal stem cells. J Control Release. 142:465–473. 2010. View Article : Google Scholar : PubMed/NCBI
17	Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra A and Ghosh PK: Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm. 202:1–10. 2000. View Article : Google Scholar : PubMed/NCBI
18	Bulte JW and Kraitchman DL: Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 17:484–499. 2004. View Article : Google Scholar : PubMed/NCBI
19	Klasen J, Blondin D, Schmitt P, Bi X, Sansone R, Wittsack HJ, Kröpil P, Quentin M, Kuhlemann J, Miese F, et al: Nonenhanced ECG-gated quiescent-interval single-shot MRA (QISS-MRA) of the lower extremities: Comparison with contrast-enhanced MRA. Clin Radiol. 67:441–446. 2012. View Article : Google Scholar : PubMed/NCBI
20	Vaage-Nilsen O: Acute, severe and anaphylactoid reactions are very rare with low-molecular-weight iron dextran, CosmoFer. Nephrol Dial Transplant. 23:33722008. View Article : Google Scholar : PubMed/NCBI